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Species of frogs and toads have proven to be a rich source of drugs and contain 
various components with potential biological activities, especially in their skin or skin 
secretions. Among these, peptides are found with broad-spectrum antibacterial and 
antifungal activities, as well as anticancer properties. It is generally assumed that 
these cationic, amphipathic and α-helical peptides constitute a part of the innate 
immune system that protects the animal from invasion by pathogenic microorganisms. 
In this thesis, a novel peptide (QUB-1342) was discovered in the skin secretion of the 
European edible frog, Pelophylax kl. esculentus. The precursor structure was found 
through applying a “shotgun” cloning method, and subsequently translating the cDNA 
to deduce the mature peptide sequence: FLPIVTGLLSGLL-NH2. From comparison 
with the sequences of known AMPs, QUB-1342 was classified as a temporin family 
member. The peptide was chemically-synthesised using solid phase chemistry and 
afterwards, its molecular mass and purity were confirmed by MALDI-TOF mass 
spectrometry and reverse phase HPLC.  
In pharmacological assays, QUB-1342 displayed a weak activity against S. aureus, 
with an MIC=64μM. It did not show any haemolytic effects at the concentrations 
employed. Further investigations are underway to seek more functions of the peptide 
and to examine the relationship between its structure and activity, and also to develop 
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Chapter 1. Introduction 
 
1.1 Introduction to Anura 
1.1.1 Overview 
Anura, an order of Amphibia comprised of frogs and toads are widely distributed 
from the tropical to subarctic areas, but the species diversity is most concentrated in 
tropical rainforests. 
 
The value of frogs has been discovered in various countries throughout time. For 
example, the exudate of the skin of Phyllobates terribilis, known as the golden poison 
arrow frog, is the traditional source of poison applied to arrows by natives hunting in 
Colombia’s rainforest. Secretion from the skin glands and parotid glands of toads is 
also one of the traditional medicines in China, where it is widely-known for its 
common use as a medicinal treatment. The gland secretions have been proven to cure 
skin infections in the past, and more recently proven to function like antimicrobials, 
central nervous system stimulants and cardiotonics (Neerati et al., 2014), 
insulin-releasers (Marenah et al., 2004), and local anaesthetics, to name but a few. As 
part of the natural pharmacy, frog toxins are so diverse that they have attracted 





1.1.2 Pelophylax kl. esculentus 
Pelophylax kl. esculentus, also known as the edible frog, belongs to the family 
Ranidae, which are commonly referred to as “true frogs”. Pelophylax kl. esculentus is 
the fertile hybrid of Pelophylax lessonae, the pool frog and Pelophylax ridibundus, 
the marsh frog, and it can be reproduced by hybridogenesis. The literal meaning of the 
name Pelophylax esculentus means both "mud" and "guardian,” which reflects their 
living habits; they will seldom deviate far from water, like the conscientious guardians 
of the muddy banks around lakes, ponds and marshes. Adult edible frogs are mainly 
green, with pale brown patches scattered on their backs varying in size and number, 
with yellow eyes and a white underside, usually covered with a few dark spots
[1]
 .  
 
 
Figure 1.1 Pelophylax kl. Esculentus
[1]
 
1.2 Antimicrobial peptides (AMPs) 
Among the wide range of compounds secreted from frog skin are peptides with 
abundant bioactivities. Neuroactive and cytolytic peptides are the two major types of 






peptides in the skin secretion of Anura. Cytolytic peptide is a more accurate term than 
simply antimicrobial peptides (AMPs), because in addition to fighting against 
microorganisms, they have also demonstrated effectiveness in anti-cancer, anti-viral, 
immunomodulatory, and anti-diabetic areas (Conlon et al., 2014). According to their 
biological functions and structural features, theses peptides are further classified into 
different families. Neuropeptides are classified as tachykinins, bradykinins, caeruleins, 
bombesins, opioids, tryptophyllins and miscellaneous peptides. Overall, most peptides 
of these six classes are often widely distributed across the investigated anuran species. 
By comparison, families of AMPs are usually found in several closely related frog 
species (König et al., 2015).  
 
AMPs, also called host defense peptides (HDPs), belong to the innate immune 
response of life activities found among all living beings. There are six major AMPs 
sources: bacteria, fungi, amphibians, insects, plants, and mammals. The number of 
peptides with antimicrobial properties is reported to be significantly higher than that 
of all previously discussed bioactive peptides from numerous frog species. AMPs 
have been proven to have the ability of eliminating or inhibiting Gram negative and 
Gram positive bacteria, enveloped viruses, fungi and even transformed or cancerous 
cells. These peptides are strong, broad-spectrum antibiotics that show potential as 




1.2.1 Structure-activity relationship of AMPs 
The distinctive activities of AMPs are created by the uniqueness and diversity of their 
constitution and structure, which is generally sequences and folding. The number of 
constitutive amino acids in one peptide generally ranges from 12 to 50. To be cationic, 
the AMPs usually consist of multiple positively charged amino acids: arginine, lysine 
or histidine. Up till now, more than 500 cationic AMPs have been found in the 
Antimicrobial Sequences Database. Additionally, they are composed of a large 
proportion of hydrophobic amino acid residues, usually above 50% or more 
(Papagianni, 2003). There are four types of the secondary structures of most AMPs 
reported to date: β-sheet, α-helix, extended, and loop (Dhople et al., 2006). α-helical 
and β-sheet AMPs are the most commonly found in Nature and the most studied so 
far. The α-helix is a right-handed-coil with the intra-chain hydrogen bond formed 
between the amide hydrogen and the carbonyl oxygen on all peptide bonds. The 
best-known examples of such AMPs are protegrin, magainin, cyclic indolicin, and 
coiled indolicin (Huang et al., 2010). β-sheet peptides consist of at least two β-strands, 
connected by disulphide bonds (Bulet et al., 2004). Many peptides are not structured 
in free solution until distributed into a biological environment and then they form their 
final conformations. These features help AMPs to partition into the biological 
membranes. The ability to bind to the lipid bilayer membrane is also one of the 




Structure-activity relationships have been studied through analysis of certain amino 
acids in the sequence, combinational library studies, and connections between 
interactions with membranes. Currently it is believed that characteristics such as 
helicity, intrinsic hydrophobicity, hydrophobic moment and the size of the 
polar/hydrophobic domain and peptide charge, are associated with the antimicrobial 
ability as well as the side effect, haemolysis (Dathe and Wieprecht, 1999).  
 
Helicity is influenced by several factors. Proline and glycine are known to block the 
formation of helical structure. The helicity of melittin is enhanced by deleting glycine 
from the N-terminal or replacing with leucine, and at the same time the antimicrobial 
and haemolytic activities are increased (Blondelle, et al., 1991). The same effect is 
present in the substitution by alanine. Inversely, substitution with proline preventing 
folding will reduce both effects by interrupting the helicity (Thennarasu and Nagaraj, 
1996). Also through modification, haemolytic effects can be weakened. The change of 
L-amino acids to their corresponding D-amino acids will disturb helix formation, but 
with no influence on the original sequence, hydrophobicity and charge (Powers and 
Hancock, 2003). Replacement of two neighbouring residues in magainin further 
resulted in decreased helicity. However, the ability of permeability in negatively 
charged membranes is not affected, suggesting that helicity is more related to the 
interaction with membranes of neutral charge than to negatively charged bilayers 




The intrinsic hydrophobicity plays another key role in the peptide-membrane 
interaction. A moderate hydrophobicity is required. First, it should be soluble in 
aqueous solution in sufficient concentration to approach the target. Second, it should 
have affinity for the phospholipid bilayer to develop disruption. Therefore, if the 
hydrophobicity is too high or too low, it will decrease these activities. The higher may 
lead to self-association or precipitation, while the lower could result in weak 
antimicrobial effects. It seems that the hydrophobicity is more directly related to the 
haemolytic activity. Blondelle and Houghten (1992) reported that the haemolytic 
effect is significantly reduced through decreasing the hydrophobicity by replacement 
of lysine for leucine in the hydrophobic region. On the other hand, substitution of 
leucine for lysine in the hydrophilic helix region helps increase the hydrophobicity 
and enhances the haemolytic effect. 
 
When the helix forms, some of the residues distribute regularly on the two sides of the 
helix, with one side hydrophilic and the other hydrophobic. The hydrophobic moment 
is introduced to measure this character, and is proportional to the size of and distance 
between the hydrophobic and hydrophilic domain. The hydrophobic moment is 
thought to be a more relevant factor than hydrophobicity (Pathak, et al, 1995). 
 
The modification of introducing positive charge is more conducive to targeting the 
Gram-positive and Gram-negative bacteria, with less influence on haemolytic activity. 
Charge plays an important role in the antimicrobial activities on identification of the 
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bacterial membranes and aggregation of peptide near the target membrane. However, 
Dathe (1999) reported through studies of magainin analogues that highly cationic 
peptides with high haemolytic effects may still not exhibit antibacterial activity. The 
larger number of cationic residues brings high affinity to negatively charged 
membranes, but disturbs the permeability process. 
 
In general, the peptide-membrane interaction is supported by a sensitive balance 
determined by many factors such as helicity, hydrophobicity, hydrophobic moment, 
and charge. By modulating some of these factors, it could enhance the antimicrobial 
effect or minimise the haemolytic effect.  
 
1.2.2 Mechanism of action of AMPs 
The mechanisms of action of all AMPs share some common features. The 
antibacterial mechanisms mainly include destruction of membrane integrity and 
interaction with certain intracellular targets. The mechanisms of these can be 
classified into two modes: actions on the membrane and actions on intracellular 
structures. 
 
The membrane-permeabilising interaction is involved in the first stage. 
Amphipathicity is a feature containing both positive charged and hydrophobic faces, 
which most AMPs acting on membranes share. The cell membrane of bacteria is rich 
in acidic phospholipids, including phosphatidylglycerol and cardiolipin, the 
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headgroups of which contains more negative charges than other phospholipids 
(Matsuzaki, 2009). As a result, the phospholipid bilayer in the outer layer of the 
bacterial cell membrane is more likely to attract the positively charged AMPs. There 
are exceptions found by Brogden, Ackermann, and Huttner (1997) that show the 
existence of the negatively charged AMPs, changing the concept that peptides must be 
cationic to kill bacteria. For example, maximin-H5 (Lai et al., 2002) from frog skin 
belongs to the anionic peptides. Then the hydrophobic face of an AMP helps the AMP 
molecule penetrate into the plasma membrane (Madani et al., 2011). During insertion, 
pores form on the membrane bilayers by ‘barrel-stave’, ‘carpet’ or ‘toroidal-pore’ 














The second mode is the disruption of intracellular molecules. Although most AMPs 
kill microorganisms by interfering with the integrity of cell membranes, in some cases 
the microorganisms with broken membranes still survive. Increasing evidence shows 
that proteins may penetrate through cell membranes to bind cytoplasmic organelles 
that are vital to cell survival or reproduction. Buforin II does not cause the leakage of 
the cell membrane of E. coli, but penetrates the cell membrane to accumulate in the 
cytoplasm and bind to DNA and RNA, resulting in bacterial death (Park et al., 1998). 
Indolicidin at 100 μg/mL completely inhibits the DNA and RNA synthesis of E. coli, 
and significantly inhibits the protein synthesis at concentrations of 150 to 200 μg/mL. 
Another AMP, thanatin, kills bacteria by inhibiting their respiration. Sarcotoxin II can 
inhibit the formation of bacterial cell walls, so that bacteria cannot maintain normal 
cell morphology and it also blocks growth (Bahar, and Ren, 2013). In general, 
intracellular binding causes the inhibition of the synthesis of cell walls and cell 
membranes, the activation of autolysins, the inhibition of DNA, RNA and protein 
synthesis (Nicolas, 2009), and the inhibition of certain enzymes. It is worth noting 
that despite the two mechanisms, the exact mechanism of killing remains unknown in 
many cases.  
 
1.3 Classification of AMPs 
There are more than 850 species in the frog family Ranidae distributed worldwide. 
Based on the sequence similarities of amino acids, AMPs from ranid frogs are 
classified into 14 families: brevinin-1, brevinin-2, esculentin-1, esculentin-2, 
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japonicin-1, japonicin-2, nigrocin-2, palustrin-1, palustrin-2, ranacyclin, ranalexin, 
ranateurin-1, ranateurin-2, and temporin (Conlon, 2008). 
 
1.3.1 Brevinin-1 
The brevinin-1 family, first discovered from the skin of the Asian frog R. brevipoda 
porsa, now reclassified as Pelophylax porosus (Morikawa, Hagiwara and Nakajima, 
1992), is widely distributed among North American species. Brevinin-1 peptides often 
consist of 24 amino acid residues, with a strongly conserved Pro
14
, which plays an 
important role in the pore formation on membranes. Another conserved sequence 
cys-3X-lys/arg-lys-cys forms a C-terminal disulphide bridge, named a Rana-box 
structure. Studies on circular dichroism have shown that brevinin-1 peptides mainly 
present as a random coil in aqueous solutions, but in a membrane simulated 
environment such as 50% trifluoroethanol, they transfer into an extended a-helical 
conformation (Kwon et al., 1998). 
 
Brevinin-1 peptides share a broad spectrum of antimicrobial effects against 
Gram-positive bacteria, Gram-negative bacteria, and pathogenic fungi, but at the same 
time, they possess a very strong haemolytic activity (Conlon et al., 2003). For 
example, the HC50 (the concentration producing 50% haemolysis) values of 
brevinin-1E from R. esculenta are less than 1 μM (Simmaco et al., 1994), which will 
largely limit its application prospects in treatment. Conlon found when the 
C-terminally loop of brevinin-1 was substituted by amidation, it could still inhibit the 
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growth of E. coli, and S.aureus, suggesting that the Rana-box structure was not 
necessary for antimicrobial activities. Kwon (1998) also found that the linearisation 
modification of a brevinin-1 analogue reduced the haemolytic effect, with antiviral 
effects being retained.  
 
1.3.2 Brevinin-2 
Brevinin-2 was first discovered from the skin of the Japanese frog P. porosus 
(Morikawa et al., 1992), and has been found widely distributed in Eurasian species. 
The primary structures of brevinin-2 peptides are very different among and within 









(Conlon et al., 2004). The brevinin-2 peptides from R. esculenta (Ali et al., 2003) 
and R. ornativentris (Sumida et al., 1998) showed strong antibacterial activity against 
E. coli (MIC<10 μM), and also had a bacteriostatic effect on S. aureus and C. 
albicans. Peptides of the brevinin-2 family show much lower haemolytic activities 
compared to brevinin-1 peptides (Simmaco et al., 1994). 
 
1.3.3 Esculentin-1 and esculentin-2 
The prototype peptides of esculentin-1 and -2 peptides were first identified in the skin 
secretion of Pelophylax lessonae/ridibundus, previously known as Rana esculenta 
complex (Conlon, 2008) and subsequently discovered in the skins of closely related 
species. The C-terminals of both esculentin-1 and esculentin-2 are stabilised by an 
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intramolecular disulphide bridge between two cysteines, developing a cyclic 
heptapeptide structure. 
 
Esculentin-1 is the longest AMPs found in Anura to date, containing as many as 46 
amino acids. The cationic residues and the C-terminal heptapeptide ring are 
specifically conserved, which occupy more than half of the primary structure. 
Esculentin-1 has a strong inhibitory effect on various pathogens such as E. coli, S. 
aureus, Pseudomonas aeruginosa Migula, and C. albicans, with MICs <1 μM.  
 
Compared with esculentin-1, esculentin-2 peptides are shorter, consisting of 37 
residues. Their cyclic heptapeptide is less conserved, and there are more amino acid 
substitutions among esculentin-2 family members, but most share similarity in Nature. 
The positively-charged amino acids and cysteine are conserved. Esculentin-2 has a 
strong antibacterial activity against E. coli and S. aureus (MIC<10 μM). At the same 
time, it also has a certain inhibitory effect on C. albicans (MIC = 30~50 μM) (Matutte 
et al., 2000; Goraya et al., 2000). 
1.3.4 Ranalexin 
Ranalexin was first discovered in an extract of tadpoles of the American 
bullfrog, Rana catesbeiana and is found only in closely-related species (Conlon et al., 
2004). It is expressed during both metamorphosis and maturity. The peptide has 20 
amino acid residues. It is α-helical, and possesses a single disulphide bridge that 
shapes an intramolecular heptapeptide loop (Clark et al. 1994). Ranalexin shows a 
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broad and strong antimicrobial activity against Gram-positive bacteria, including 
Methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis Evans and 
Streptococcus pneumoniae Chester. However, against some of the very important 
Gram negative pathogens in clinical infections, such as Pseudomonas aeruginosa and 
Proteus mirabilis Hauser, it has no effect. 
 
1.3.5 Ranatuerin-1 and Ranatuerin-2 
Ranatuerin-1 is found only in the skin of the three closely related species, the 
American bullfrogs Rana catesbeiana, R. clamitans and R. grylio (Conlon et al., 
2004). It contains 25 amino acid residues and a C-terminal heptapeptide ring. Studies 
have shown that the peptide exhibited growth-inhibition against E. coli, S. aureus, and 
C. albicans, but the haemolytic activity on human erythrocytes was relatively weak 
(Goraya et al., 1998). The replacement of the cysteine residues of ranatuerin-1 by 
serine had little effect on its conformation and bioactivity, indicating that the cyclic 
structure is not required for the antimicrobial activity of ranatuerin-1. 
 
The ranatuerin-2 family was first isolated from the skin of the American bullfrog R. 
catesbeiana (Goraya et al., 1998), and is widely distributed in North American and 
Asian ranid frogs. The numbers of amino acids in currently identified ranatuerin-2 


















), being conserved. The variation 
16 
 
of sequence of the ranatuerin-2 family contributes to its broad spectrum of 
antimicrobial potencies. The family has activity against E. coli (MIC=2~30 μM) and S. 
aureus (MIC=2~200 μM), while activity against C. albicans is generally low. The 
haemolytic effect ranges from 35 μM to >200 μM. 
 
1.3.6 Temporin 
Temporins are a huge antimicrobial peptide family. Temporins were initially 
discovered in the skin of the European red frog, Rana temporaria in 1996 (Simmaco 
et al., 1996) and were found in many frog species of Northern American and Eurasian 
origin, but also in the venoms of wasps (Conlon et al., 2004). Temporins are a large 
family of more than 40 types. It is one of the smallest amphiphilic α-helical AMPs 
found in Nature, consisting of 10 to 14 amino acid residues. The properties of the 
temporin family are as follows: 
Among the already found amphipathic a-helical AMPs, temporins contain the smallest 
number of amino acids, ranging from 10 to 14. Compared with other cationic AMPs, 
most temporins are mildly cationic peptides, which are usually charged from 0 to +3 
in neutral environments. Unlike post-translational modifications in other peptides of 
Ranidae (Simmaco et al., 1998; Conlon et al., 2004), temporins lack the ‘Rana box’ 
modification - the heptapeptide ring of the C terminus. Instead, the C terminals of 




Temporins are active on an extensive range of pathogenic microorganisms, including 
bacteria, viruses, fungi and protozoa. Nevertheless, they are non-toxic to human and 
animal cells. Most are active against Gram-positive bacteria, such as 
methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus 
faecium and Enterococcus faecalis, with minimum inhibitory concentrations in the 
range of 2.5 to 20 μM (Wade et al., 2000; Giacometti et al., 2005). Some temporins 
also kill fungi, such as Batrachochytrium dendrobatidis, a fungus which resulted in 
the reduction of global amphibian populations (Rollins-Smith et al., 2003), and C. 
albicans (Simmaco et al., 1996). Temporin L was shown to have broad spectrum 
antibiotic activity against Gram-positive, Gram-negative bacteria and yeasts (Rinaldi 
et al., 2002). 
 
The study of the structure/activity relationships of temporin A showed that the 
hydrophobic N-terminal residues, seventh positive amino acid residue and the 
hydrophobic residues of the fifth and the twelfth sites, are of great importance to the 
antibacterial activity (Wade, et al., 2000). The antimicrobial ability is improved by 
substitution of leucine for isoleucine. In most cases, the antibacterial potency is 
directly associated with the net positive charge of temporins. However, there is no 
positive charge in the temporin-1Od molecule and it possesses a strong antibacterial 
activity with an MIC against S. aureus of 13 μM (Kim, Iwamuro, Knoop and Conlon, 





1.4 Significance of AMP research and development 
Today, bacterial infection and bacteria-related diseases are on the rise. One of the 
important reasons is attributed to the formation of bacterial resistance, such as 
drug-resistant Mycobacterium tuberculosis, Escherichia coli, and the notorious 
methicillin-resistant Staphylococcus aureus (MRSA), known as super bacteria. How 
to overcome bacterial resistance and develop new antibacterial agents is the hotspot of 
current research. Among possible solutions, AMPs have gained considerable 
promising prospects, for their broad spectra of actions, abundant species and highly 
effective bactericidal activity, and not readily effecting drug resistance. 
 
AMPs directly kill microorganisms through membrane disruption and internal target 
interference. In addition, they possess antiviral and immune modulation activities 
among many others. The development of AMPs is underway. Magainin from the 
African clawed frog had been developed as a treatment for impetigo and diabetic foot 
ulcers. It was one of the great attempts although it failed to pass the US Food and 
Drug Administration (FDA) hurdle. 
 
The limitations of AMPs retard the research and development of clinical agents to 
some extent. The first obvious defect is that peptides are easily broken down by 
proteases in vivo, which reduces their bioavailability as well as efficacy. Some 
methods have been developed to overcome this such as structural alternation by 
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D-amino acids and nonpeptidic backbones, or changing of dosage forms. Secondly, 
peptides come at a high cost. Solid peptide synthesis in laboratory research is too 
expensive to be applied in large-scale manufacture. Genetic engineering may 
overcome part of the questions through recombinant DNA and bacteria and fungi 
fermentation. Another issue exists in the uncertain mechanism of AMPs, causing 
doubt of potential side effects and toxicity (Hancock and Sahl, 2006).  
Research on AMPs has a long way to go. It is believed that AMPs will play an 




1.5 Aims and objectives of this research 
 
- To construct a cDNA library from Pelophylax kl. esculentus skin secretion and 
interrogate this with degenerate primers in a “shotgun” cloning technique to identify 
transcripts encoding the biosynthetic precursors of novel peptides. 
- To predict the structures of novel peptides encoded by these precursors and to locate 
mature peptides in HPLC fractions of the same skin secretion. To confirm primary 
structures through MS/MS fragmentation sequencing. 
- Once structures are confirmed, the peptides will be chemically synthesised to 
generate sufficient quantities for biological screening purposes. 
- Biological screening will be performed using a variety of functional assays, both 




Chapter 2. Materials and Methods 
 
2.1. Animals and skin secretion harvesting 
Specimens of edible frog, Pelophylax kl. esculentus (n = 30) were obtained from a 
commercial source (Le QuerruyCellier, Notre Dame de Monts, France) and had been 
captive bred. All frogs were adults and defensive skin secretion was harvested after 
which frogs were released. They were maintained in the purpose-designed amphibian 
facility at 18-25°C under a 12h/12h light/dark cycle. They were fed 
multivitamin-loaded crickets three times per week in the animal facility in Queen’s 
University Belfast.   
Defensive skin secretions of the frogs were obtained by two methods. The first one 
was a mild electrical stimulation (6V DC; 4 ms pulse-width; 50Hz) (C.F. Palmer, UK). 
This method was used to stimulate the glands to secrete on the dorsal surface of frogs, 
each of 20 s duration. Each animal was restrained and a bipolar electrode of 21 G 
platinum moved along the moistened dorsal skin surface. By this method, the glands 
in the surface of skin were stimulated to secrete. Distilled deionised water was used to 
wash the secretion from the surface of the skin and this was collected into a chilled 
glass beaker. Liquid nitrogen was used to freeze the skin secretion, then this was 
freeze-dried in an ALPHA 1-2/LD freeze dryer (Germany) and stored at –20 °C 
before use. The other and preferred technique was gently massaging the dorsal skin 
surface with a latex-gloved finger and this method was found to be equally effective. 
Secretion washings were treated as described before. Both techniques caused no harm 
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and minimal stress to the animals. All the procedures were subject to ethical approval 
and carried out under appropriate UK animal research personal and project licenses. 
 
2.2 Molecular cloning 
2.2.1 mRNA isolation 
Poly-A mRNA was isolated from the lyophilised skin secretion with a Dynabeads
®
 
mRNA DIRECT™ Kit (Dynal Biotech Ltd, UK). Polyadenylated mRNA was isolated 
from stabilisation buffer with the use of magnetic oligo-dT beads in the kit and this 
relies on A_T base pairing. At the 3’ end of mRNA, the poly-A tails anneal to the 
oligo-dT forming mRNA-dT polymers. The mRNA can be isolated from the secretion 
after washing and elution. The operation in detail was as follows: 
Preparation of sample lysate 
5 mg of lyophilised skin secretion from Pelophylax esculentus were dissolved in 1 ml 
of lysis/binding buffer (Dynal Biotech, UK) in a 1.5mL tube to remove the mRNA 
from any cells. The tube was shaken for a few seconds and then returned to the ice, 
alternately for 20min. After 20min extraction, the tube with sample was centrifuged at 
18,000 × g for 5 min in an Eppendorf Centrifuge 5424 (Eppendorf, Germany). 
Prepration of Dynabeads
®
 Oligo (dT)25 beads 
250 µl of Dynabeads Oligo(dT)25 (5 mg/ml) suspension was added to another 1.5ml 
RNase-free tube and this tube was placed on a Dynal MPC-S magnet for 5 min. The 
supernatant in the tube was discarded carefully as cleanly as possible. 
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250 µl of Lysis/Binding buffer was added to the beads tube and the tube was placed 
on the Dynal MPC-S magnet for a few minutes. The supernatant was then discarded 
carefully. The tube was kept at the magnetic rack.  
Hybridisation between the poly-A tail of mRNA and bead-bound oligo-dT  
The supernatant from the lysate solution was transferred into the 1.5 ml tube 
containing prepared beads which were combined with oligo-dT on the surface by 
covalent binding. The mixture of lysate and beads were blended by slowly and gently 
shaken for 15 min at room temperature, which made the poly-A tail of mRNA 
hybridise to the bead-bound oligo-dT through A-T base pairing. Finally, the 
supernatant was discarded completely on the magnetic rack. The intact mRNA was 
isolated from the secretion and retained on the surface of the beads. 
Washing 
The mRNA/beads complex was washed with 500 µl of Buffer A three times and then 
washed with 500 µl Buffer B two times. The beads were separated from the washing 
solution and the washing solution was discarded on the magnetic rack after each 
washing step. Finally, all the liquid was discarded. 
Elution 
This used 18 µl of the elution solution (10 mM Tris-HCL) to elute the mRNA from 
Dynabeads. Then the tube was incubated at 80°C for 2 min. After this, it was placed 
on the magnet rack followed by transfer of all the supernatant by pipette to a 0.2ml 




Figure 2.1 Outline of the protocol for isolating mRNA from a crude starting sample 




2.2.2 cDNA library construction 
The cDNA library was constructed by using a BD SMART
TM
 RACE cDNA 
Amplification Kit (BD Bioscience Clontech, UK). First-strand synthesis was primed 
using a modified oligo (dT) primer. After reverse transcriptase reaches the end of the 
mRNA template, it adds several dC residues. The BD SMART II A Oligonucleotide 
anneals to the tail of the cDNA and serves as an extended template for BD 
PowerScript RT. 5’ RACE Ready cDNA was synthesised using a 5’-RACE CDs 
Primer and the BD SMART II™ A Oligonucleotide which contained a terminal 
stretch of G residues to pair dC-rich cDNA tail at the end. 3’-RACE-Ready cDNA 
was synthesised using 3’-RACE CDs Primer by a reverse transcription reaction. 
Table 2.1 The sequence of primer BD SMART II, 3’-CDS Primer A and 5’-CDS 
Primer 
Primer Sequence 
BD SMART II 





(N = A, C, G, or T; V = A, G, or C) 
5'–(T)25V N–3' (N = A, C, G, or T; V = A, G, or C) 
 
Preparation of mixture for 3’ RACE Ready cDNA synthesis and 5’ RACE Ready 
cDNA synthesis 
The following reagents were combined in three 0.2 ml PCR tubes respectively. One 
extra volume of reagents was calculated and added to ensure sufficient volume for the 
RT-PCR reaction.  
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Table 2.2 The components of the 3’ RACE cDNA reaction 
Component Final Volume Final Concentration 
RNA sample 4 μl 10-1000 ng 
3’-RACE CDS Primer 1 μl 12 μM 
dNTP Mix 1 μl 4 mM                                                                                                                    
DTT 1 μl 4 mM 
5× First-Strand Buffer,30mM MgCl2 2 μl 1 × 
Reverse Transcriptase 1 μl 20 unit 
*The Master Mix includes dNTP Mix, DTT and 5× First-Strand Buffer for 5 
reactions.  
Table 2.3 The components of the 5’ RACE cDNA reaction 
Component Final Volume Final Concentration 
RNA sample 3 μl 10-1000 ng 
5’-RACE CDS Primer 1 μl 12 μM 
BD SMART II
™
 A Oligonucleotide 1 μl 12 μM 
dNTP Mix 1 μl 4 mM 
DTT 1 μl 4 mM 
5× First-Strand Buffer,30mM MgCl2 2 μl 1 × 
Reverse Transcriptase 1 μl 20 units 
*The Master Mix includes dNTP Mix, DTT and 5× First-Strand Buffer for 5 
reactions. 
Reverse transcription polymerase chain reaction (RT-PCR) 
After preparing each solution, they were mixed thoroughly and transferred into PCR 
tubes, then centrifuged briefly. The tubes were incubated at 70°C for 2 min. This step 
allows the primer to bind to the template. After this, it was cooled on ice for 2 min. 
The mixture was centrifuged at 5000 × g to concentrate the liquid. 
A master mix was made as following in each reaction tube (already containing 5µl): 
2µl 5× first-strand buffer, 1µl DTT (2mM), 1µl dNTP Mix(1mM), 1µl BD 
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PowerScript Reverse Transcriptase(10 Unit/µl). The contents of the tubes were mixed 
by gentle pipetting. The tubes were centrifuged briefly to collect the contents at the 
bottom. Each tube was incubated at 42°C for 1.5 h in a thermal cycler in the PCR 
machine. Then 50µl of PCR grade water were added to each tube and these were 
returned to the PCR machine at 72°C for 7 min. The samples were then stored in a 
-20°C freezer. 
The 3’-RACE and 5’-RACE Ready cDNA amplification products could be stored at- 
20°C for up to 3-12 months.  
2.2.3 RACE-PCR 
Preparation of mixture for RACE-PCR reaction 
The following reagents were mixed in a PCR tube. And an extra volume was 
calculated and added to ensure sufficient volume for the RACE-PCR reaction. 
Table 2.4 The components of the RACE-PCR reaction 
Reagent Volume Final concentration 
PCR-Grade Water 3.1 µl  
10× BD Advantage 2 PCR Buffer 1.5 µl 1.5× 
dNTP Mix (10 mM) 0.2 µl 0.2 mM 
NUP (20 µM ) 0.5 µl 1 µM 
Sense Primer (20 µM)/Anti-sense primer 0.5 µl 1 µM 
50 × BD Advantage™ 2 Polymerase Mix 0.2 µl 1 × 
cDNA library  5 µl  
The two negative control tubes were added with 5 µl PCR-Grade Water instead. 
3’ RACE-Ready cDNA amplification 
The 3’-RACE reaction employed a nested universal primer (NUP) supplied with the 
BD SMART
TM
 RACE cDNA Amplification Kit (BD Bioscience Clontech, UK), and 
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a sense primer (5’-GAWYYAYYHRAGCCYAAADATGTTCA-3’) that was 
designed to a segment of the 5’-untranslated region of peptide cDNAs previously 
cloned from the skin of Pelophylax esculentus.  
The sample and negative control tubes were transferred into a PCR machine and then 
a programme was initiated to amplify the cDNA. The thermal cycling parameters 
were as follows:  
Table 2.5 3’/5’-RACE PCR programme 
Stage  Parameter 
Stage 1 initial denaturation at 94°C for 1min 
Stage 2 40 cycles (denaturation at 94°C for 30 s, primer annealing at 
62°C for 30 s, extension at 72°C for 3 min ) 
Stage 3 final extension at 72°C for 10 min 
The annealing temperature in one group included one 3’ RACE-Ready cDNA 
template and one negative control at 60°C, whereas it was set at 62°C in another 
group.  
The PCR cycles were stored at 4°C, making preparation for the agarose gel analysis 
and purification.  
5’ RACE-Ready cDNA amplification 
5’-RACE PCR was almost the same process as 3’ RACE PCR, except for adding 5ul 




2.2.4 Agarose gel electrophoresis for RACE-PCR product 
Gel electrophoresis is a method that can separate DNA fragments on the basis of their 
different sizes. Through comparing the sample band on the gel with those of the DNA 
calibration ladder, the size of sample DNA fragments can be determined. Different gel 
pore sizes will have different formulae. 
Preparation of 1.5% agarose gel 
0.45g agarose (Invitrogen, UK) was weighed and dissolved in 35ml of 1×TBE buffer 
(Invitrogen, UK) in a conical flask. A microwave oven was used to heat the 
suspension until all the agarose had dissolved. The flask was then cooled to around 
60 °C. 3.5μl of ethidium bromide (EtBr, 10 mg/mL) (Invitrogen, UK) were added to 
the flask and shaken gently to mix. Two combs were inserted in the gel-forming block 
which was placed in a dry Consort E122 gel electrophoresis tank (Consort, Belgium). 
The melted agarose was then poured into the gel tank, ensuring that all bubbles were 
eliminated. After approximately 40 min the liquid gel solidified. The combs were 
removed carefully and the wells were generated. 1×TBE Buffer was poured into the 
gel electrophoresis tank. The buffer was added to just above the surface of gel. 
Gel electrophoresis analysis 
1.5μl PCR product was mixed with 0.5μl loading dye (0.25% bromophenol blue, 15% 
Ficoll 400 in TAE) by pipetting. Then the mixture was transferred to the gel wells by 
pipette. 2.5μl of DNA ladder (Invitrogen, UK) was loaded into the first well of the gel. 
90 V were used to perform the electrophoresis for 30 min until the yellow colour 
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indicator reached two-thirds down the gel. Then the gel was removed from the gel 
tank for later detection. 
Detection of bands and gel analysis 
The electrophoresis gel was placed under the UV trans-illuminator BioDoc-It
®
 
Imaging System (NVP, Cambridge, UK) and a photographic image was recorded as 
the result. The DNA bands of the samples were compared with those of the ladder to 
determine whether the DNA amplification was successful or not. The 1× TBE Buffer 
was recycled and the samples were stored at -20°C in the freezer. 
2.2.5 Purification of RACE-PCR product 
A Rapid PCR purification system was used to perform the PCR product purification 
(Marligen Biosciences Inc, USA). The DNA amplification products from the previous 
steps were miexed and merged into one tube. Then, 4 to 5 times of volume of Buffer 
CP were added into the 1.5 ml tube. A purification column was used here. The 
purification column was placed into a 1.5 ml tube. The solution was transferred drop 
by drop onto the centre of a filter cartridge into the purification column and 
centrifuged at 5000 × g for 1 min. Then the liquid at the bottom of the tube was 
discarded and the purification column was retained. The purification column was 
placed into a new tube, and 700μl of washing buffer were added to the column, then 
centrifuged for 1 min at 8000 × g. Subsequently, the filtrate was discarded and the 
collection tube was placed back in the bottom of the cartridge. Similarly, 500 μl DNA 
Washing Buffer were also added into the cartridge and centrifuged again at 8000 × g 
for 1 min. Then, the filtrate was discarded and the collection tube was placed back 
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into the cartridge. Finally, the empty cartridge with collection tube was centrifuged at 
the maximum speed of 8000 × g for 2 min to dry the column matrix and remove 
ethanol completely as this could interfere with the downstream applications.  
The purification column was placed into a new tube and 30μl of PCR grade water was 
added to the column. The column was left for 2 min so that the sample could dissolve 
in the water and when centrifuged, the sample DNA would permeate through the filter 
at the bottom of the column with the water. Then the tube was centrifuged for 1 min 
and the flow-through liquid, containing the PCR product DNA, was retained. 
Finally, the DNA purification products were placed for 50 min in a concentrator 
(Eppendorf, Hamburg, Germany) to dry the DNA sample and drive the ethanol away 
thoroughly. After evaporation, the DNA sample was sealed with parafilm and stored 






-T Easy Vector (Promega, USA) kit was used for ligation, 
transformation, blue and white colony screening and isolation of recombinant DNA 
reactions. The DNA with A at both ends of the strand could bind to and insert into the 
site of the pGEM
®
-T Easy Vector (50 ng/μl) with T through A-T based pairing.  
Reagent preparation  
Ten μl of deionised water were added into the 1.5 ml tube containing 7 μl DNA 
purification products to dissolve the DNA and then tube was vortexed completely by 
tapping and micro-centrifuged briefly to collect all contents at the bottom and then 
placed on ice to cool. This step was repeated five times for DNA preparation. 2× 
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Rapid Ligation Buffer was vortexed vigorously without centrifuging as the Buffer was 
so heavy. Also, the pGEM
®
-T Easy Vectors were micro-centrifuged briefly without 
pipetting to avoid damaging the fragile vectors. The T4 DNA Ligase was also 
micro-centrifuged briefly without pipetting as the enzyme was susceptible to 
inactivation under the changes of environment. 
Ligation between DNA and vector 
The following prepared reagents were combined and mixed without pipetting in a 
DNase-free PCR tube.  
Table 2.6 The components of the ligation reaction 
Component Volume Final Concentration 
2× Rapid Ligation Buffer,20mM MgCl2 2.5 μl 1 × 
pGEM
®
-T Easy Vectors 0.5 μl 50 ng/μl 
PCR Products 1.5 μl 10-1000 ng 
T4 DNA Ligase 0.5 μl 3 Weiss units 
 
A 0.2 ml PCR tube with ligation reaction product was incubated for 1 h at room 
temperature and then incubated at 4°C overnight (16-24 h) in the thermal cycler. The 
vectors with a 3’ single terminal thymidine (T) in the insertion site were re-cyclised 
with a single guanosine (A)-ending DNA sequence derived from Taq DNA 
Polymerase through A-T base pairing. 
2.2.7 Transformation 
The recombinant vectors were transformed into the competent cell and selected by 








Preparation of LB/ampicillin/IPTG/X-Gal plates 
6.4 g of LB Agar (Invitrogen, UK) were added into a glass flask, then 200 ml of 
deionised water were added. The solution was autoclaved for sterilisation. When the 
solution was ready to use, 550 μl of ampicillin were added into the bottle and shaken 
to mix. 11 ml of agar mixture were placed into standard Petri dishes and these were 
left to solidify. The LB agar plates could be stored at 4°C. After solidification, 100 µl 
of IPTG (100mM, Promega, USA) were spread slowly and gently over the surface of 
each LB-ampicillin plate with a spreader, which induced the expression of lacZ gene. 
Subsequently, 20 μl X-Gal as a chromogenic substrate, was added and spread over the 
surface completely in a dark environment and this reacted with β-galactosidase and 
was detected by a colour change. All the plates were incubated upside down keeping 
the water inside the agar for 45 min at room temperature, and then the plates were 
ready for bacterial culture.  
Transformation  
The DNA ligation product was placed on ice from the PCR Amplifier. The sample 
were transferred into a 1.5 ml tube. The competent JM109 E.coli bacteria stored in 
-80°C was defrost on ice for about 4 min. Then 50μl of bacteria suspension were 
added into the sample tube. Both were mixed by gently flicking and tapping at the 
bottom of the tube three times and then returned back to ice for 20 min. The mixture 
was heat-shocked in an incubator at 42°C for 47 s, then transferred to ice immediately 
for 2 min. Finally, 950μl of SOC medium were added into the mixture tube which was 
placed into a shaking incubator at 150 rpm and 37°C for 2.5 h.  
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Plating and culture for amplification  
When incubation had finished, 100 μl of transformation suspensions were transferred 
and spread over the surface of LB/ampicillin/IPTG/X-Gal plates. All plates were 
incubated upside down at 37°C overnight (16-24 h) for bacterial culture and DNA 
amplification.  
2.2.8 Blue and white colony screening 
Before the bacteria were transferred, three plates were prepared. Each plate was 
separated into 18 individual areas. There were three kinds of colonies found growing 
on the LB/ampicillin/IPTG/X-Gal plates from the previous procedures including 
white colonies, blue colonies and white colonies with a blue dot. The white bacterial 
colonies were readily differentiated from the blue colonies and were marked. The 
white bacteria were the targets because they had been successfully transfected with 
the vectors containing the ligated DNA products. The blue colonies were from the 
bacteria without vectors. The white bacterial colonies were then selected and 
subcultured by an inoculating loop onto the 18 areas that were already prepared on the 
plates under a sterile environment. All the plates were then incubated upside down at 
37°C overnight (16-24 h) for subculture and further selection. 
2.2.9 Isolation of recombinant DNA by cloning PCR 
A single DNA was isolated and amplified by the cloning PCR reaction, in which the 
M13 Forward Primer (5’-GTAACGCCAGGGTTTTCCCAG-3’) and M13 Reverse 
Primer (5’-TGTGAGCGGATAACAATTTCAC-3’) bound to the 5’ and 3’ ends of 
inserted DNA, respectively by use of an Advantage
®




White colonies of bacteria from the second incubation were picked up and transferred 
to the tubes with 20 μl deionised water for dispersion. Then, 14 samples of bacteria 
were obtained for recombinant DNA isolation.  
Vector release 
All the tubes were vortexed briefly and placed to a heating block to incubate at 100 °C 
for 5 min, then cooling down on ice for 5 min in order to make the cells fragile. Then, 
each tube was vortexed for 30 s. After vortexing, the tubes were centrifuged at 8000 × 
g for 5 min to ensure the recombinant plasmid DNA was released to the supernatant. 
Preparation of reagent mixture for cloning PCR 
The following components were combined and mixed completely by pipetting. One 
extra volume of reagents was calculated and added.  
Table 2.7 The components in each cloning PCR reaction  
Component Final Volume Final Concentration 
dNTP Mix 1 μl 0.2mM 
PCR-Grade water 31 μl - 
Cloning PCR Buffer 10 μl 1 × 
M13 Forward Primer 2.5 μl 5 μM 
M13 Reverse Primer 2. 5 μl 5 μM 
Taq Polymerase enzyme 0.25 μl units 
DNA template  2.5 μl 10-1000 ng 
*The Master Mix includes PCR-Grade water, dNTP Mix, Cloning PCR Buffer, M13 
Forward Primer and M13 Reverse Primer for 14 reactions. 
The Master Mix was prepared in a 1.5 ml tube. 47μl of Master Mix were transferred 
to each new 0.2 ml PCR tube. Then, 0.25 μl Taq Polymerase enzyme and 2.5 μl 
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supernatants containing recombinant DNA were added into each 0.2 ml PCR tube in 
proper order and pipetted completely and evenly. All of the fourteen 0.2 ml PCR 
tubes were micro-centrifuged briefly to collect all contents at the bottom without 
bubbles. The isolation of target DNA from the vector and target DNA amplification 
relied on a cloning PCR reaction in which the M13 Forward Primer and M13 Reverse 
Primer could bind to the 5’ and 3’ ends of inserted DNA, respectively. Finally, the 
cloning PCR reaction was set and commenced using the following programme: each 
cycle in the thermal cycler is shown in Table 2.8. After this cloning PCR reaction, the 
14 samples tubes were stored at -20°C in the freezer. 
Table 2.8 PCR programme of cloning 
Stage  Parameter 
Stage 1 initial denaturation at 94°C for 1min 
Stage 2 31 cycles (denaturation at 94°C for 30 s, primer annealing at 
55°C for 30 s, extension at 72°C for 3 min ) 
Stage 3 final extension at 72°C for 10 min 
 
2.2.10 Agarose gel electrophoresis analysis of cloned PCR product 
The process was almost same as in section 2.2.4, except that the 1.5μl 
coloured-samples from fourteen tubes were loaded respectively without additional 
loading dye. 
The electrophoresis gel was removed to a UV trans-illuminator BioDoc-It
®
 Imaging 
System (NVP, Cambridge, UK) and the a image was recorded as a result. According 
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to the principle that the molecular weight was 200 bp higher than the RACE-PCR 
result, the DNA band of the samples was compared with the ladder to determine 
whether the target DNA was of expected size or not. In addition, the TBE Buffer was 
recycled and all samples were stored at -20°C in the freezer. 
2.2.11 Selected PCR product purification 
An E.Z.N.A.
®
 Tissue DNA Kit (Omega, Norcross, UK) was employed in PCR 
product purification, in which DNA was bound to silica-based filter membranes 
during washing steps and eluted for collection. 
This process was the same as that described in section 2.2.5.  
Finally, the fourteen DNA samples were stored at -20°C in the freezer. 
2.2.12 DNA sequencing  
The sequencing reaction was performed using A BigDye
®
 Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, California, USA) in which the sequence was 
detected by fluorescence during DNA extension and termination process. 
Preparation of mixture for sequencing PCR reaction 
Some of the DNA samples were selected for the sequencing reaction. The components 
of master mix in this step are shown below, and an extra volume was calculated and 
added to ensure sufficient volume for the sequencing PCR reaction.  
Table 2.9 The components of a sequencing PCR reaction 
Component Final Volume Final Concentration 
PCR-Grade water 12.4 μl - 
5× Sequencing Buffer 3.57 μl 1 × 
M13 Forward Primer 1.14 μl 0.8 μM 
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Terminator Ready Reaction Mix  2.86 μl 13.68% 
DNA template  2.5 μl 10-1000 ng 
*The Master Mix includes PCR-Grade water, 5X Sequencing Buffer, M13 Forward 
Primer and Terminator Ready Reaction Mix for 4 reactions. 
DNA sequencing reaction 
Master Mix and 2.5 μl sample were added into 0.2 ml PCR tubes Then the tubes were 
centrifuged briefly and placed into the PCR Amplifier. The programme was set to 
“sequencing”. The thermal cycling parameters were as shown in Table 2.10. Finally, 
the four sequencing products were stored at -20°C in the freezer. 
Table 2.10 PCR programme for sequencing reaction 
Stage  Parameter 
Stage 1 initial denaturation at 96°C for 1min 
Stage 2 26 cycles (denaturation at 96°C for 20 s, primer annealing at 
55°C for 10 s, extension at 60°C for 4 min ) 
Stage 3 Cooling at 4°C for 7 min 
 
Extension product purification by ethanol  
Before the extension product purification step, 95% ethanol and 70% ethanol were 
prepared by mixing 100% ethanol and PCR-grade water in appropriate percentages. 
72 µl of 95% ethanol were added to each sequencing reaction product and mixed by 
pipetting gently before transferring quickly to the 1.5ml tubes with 10 µl of 
PCR-grade water. All the tubes were vortexed for 30 s and kept at room temperature 
for 20 min and then centrifuged at the maximum speed of 10000 × g for 20 min.  
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Immediately after this, the supernatants were discarded as cleanly as possible. 
Similarly, 260 μl 70% ethanol were added into each 1.5 ml tube with sequencing 
reaction products and mixed, vortexed for 30 s and centrifuged again as before. Then 
the supernatants were discarded quickly. A one-min cooling step and a one-min 
heating step at 95°C were repeated 3 times. Finally, the contents of the 1.5ml tubes 
were concentrated for 3 h to dry the DNA and to evaporate the ethanol. Finally, the 
samples were stored at -20°C in the freezer. 
Sample preparation for sequencing 
All the tubes with ethanol-purified products were placed in the concentrator for 1 h 
with the lids of the tubes open. 10 μl of highly-purified HiDi formamide were added 
to each tube with DNA sample. All the tubes were vortexed and then centrifuged 
briefly as before. Then the tubes were placed in a heating block to incubate at 95°C 
for exactly 4 min before being transferred to ice and cooled for at least 3 min. After 
briefly centrifugation, 9 μl of well-prepared mixture sample was loaded into the 
96-well plate in odd or even rows. The sequencing results were obtained using an ABI 
3100 automated sequencer (Applied Biosystems, Foster City, CA, USA). The 
elongation of DNA strands in the solution was terminated by the modified ddNTPs 
randomly and detected by fluorescence. 
Sequence analysis  
After the sequencing, the nucleotide sequences of the DNA strands were obtained. 
Then the Expert Protein Analysis System (ExPASy) translate tool 
(http://web.expasy.org/translate) was applied to translate base sequences into protein 
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sequence while the Basic Local Alignment Search Tool (BLAST) 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to search for proteins similar to the 
sequenced product. At this point, the putative nucleotide and translated open reading 
frame amino acid sequence of cloned cDNA encoding precursor were obtained and 
subjected to further mass spectrometry identification. 
 
2.3 Solid phase peptide synthesis 
The novel mature peptide was chemically-synthesised by solid phase 
Fluorenylmethoxycarbonyl (Fomc) chemistry in a PS4 automated solid-phase 
synthesiser (Protein Technologies, Inc, Tucson, AZ, USA). The translated primary 
structure of the novel peptide was as follows: FLPIVTGLLSGLL-NH2.  
2.3.1 Peptide synthesis 
All of the amino acids except the last one in the sequence, were weighed and mixed 
with 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU) activator in equal proportion and in three-fold molar excess and added to the 
vials. The vials were sealed with a cap and spanner. Then, 0.3 mmol rink amide resin 
which contained an amide group for the C-terminus was also weighed into the 
reaction vessel. The bottles placed on the machine were filled with reagents as follows: 
DMF (Dimethylformamide) in bottle 1 and bottle 2, piperidine: DMF= 1:4 in bottle 3, 
NMM(N-Methylmorpholine):DMF=11:89 in bottle 4, DCM (Dichloromethane) in 
bottle 5. Vials which contained amino acids were placed in the slot position of the 
SPPS machine in an inverted order of the sequence. A nitrogen environment was 
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needed. The glass flask containing the resin, was placed on the machine as well. Then 
the synthesis programme was initiated.  
During the peptide synthesis reaction, the reaction vessel and pipeline were firstly 
washed by DMF. Then the Fmoc protecting groups were deprotected by DMF with 
piperidine. Each amino acid residue was activated and coupled using NMM and DMF 
combined with activator HBTU. During these processes, the peptide was synthesised 
from C-terminal to N-terminal. Finally, DCM was employed for washing the 
peptide/resin complex after the synthesis reaction. After the synthesis, the product was 
left to dry in the glass flask. 
2.3.2 Peptide cleavage  
The resin linked with synthesised peptide was weighed and transferred into a 50 ml 
round-bottomed flask with a magnetic rotor. The volume of cleavage cocktail was 
calculated according to the weight of the product. Cleavage cocktail containing 94% 
(v/v) trifluoroacetic acid (TFA), 2% (v/v) Thioanisole (TIS), 2% (v/v) water and 2% 
(v/v) 1,2-Ethanedithiol (EDT) were added into the 50 ml round-bottomed flask to 
deprotect the protecting groups of side chains. The cleavage and deprotection reaction 
was allowed to proceed at room temperature for 4 h, with continuous stirring. After 
that, the mixture was suction filtered using the Buchner funnel to remove the resin in 
the upper layer. The solution in the lower layer was transferred into a 50 ml universal 




2.3.3 Peptide washing 
The 50 ml universal tube was centrifuged at a speed of 5000 × g for 5 min to collect 
the peptide precipitate at the bottom and then the supernatants were discarded as 
cleanly as possible. Then, 45 ml ether was refilled and the washing step was repeated 
three times. After the last step of discarding the supernatant, the product was dried at 
room temperature. 
2.3.4 Peptide lyophilisation  
The dry peptide was dissolved in TFA/water/acetonitrile (0.5/19.95/80, v/v) (Buffer B) 
and TFA/water (0.5/99.95, v/v) (Buffer A). The peptide solution was lyophilised 
using the Alpha 1-2 freeze-drying system (Martinchrist, Germany). Finally, the 
lyophilised peptide was weighed and stored at -20°C in the freezer.  
2.3.5 Peptide calculation 
The molecular weight of the peptide was calculated by an online tool called Peptide 
Property Calculator (www.pepcalc.com). The yield of the peptide was then calculated 
to assess the success of the peptide synthesis.  
2.3.6 Reversed-phase high performance liquid chromatography (HPLC) 
1 mg of crude lyophilised peptide was weighed and dissolved in a 1.5 ml tube with 
Buffer A and Buffer B in certain ratio according to the polarity. After fully vortexed 
and 15 min centrifugation at the maximum, the clear supernatants were transferred 
into another 1.5 ml tube. An analytical reverse phase HPLC Jupiter C5 column 
(250nm × 4.6 mm, Phenomenex, UK) was washed with Buffer B for 30 min and 
equilibrated in Buffer A for 30 min before use. During operation, 1 ml of clear 
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supernatant was injected into the Jupiter C5 column on a Cecil Adept CE4200 HPLC 
system (Cecil, Cambridge, UK) with 214nm wavelength detection. The peptide was 
eluted from the column using a linear gradient from 100% Buffer A to 100% Buffer B 
over 80 min at a flow rate of 1 ml/min. The fractions were collected in polypropylene 
tubes (Sarstedt, Germany) at every peak and utilised for identification.  
2.3.7 Peptide analysis by matrix-assisted laser desorption ionisation time-of-flight 
mass spectrometry (MALDI-TOF MS) 
MALDI-TOF mass spectrometry was used for peptide identification by mass analysis 
using a linear time-of-flight mass spectrometer (Voyager DE, PerSeptive Biosystems, 
Framingham, MA, USA) in positive detection mode. 2 μl of samples were loaded and 
spotted onto the MALDI ground-steel target plate and left to dry. Then, 1 μl of matrix 
solution (10 mg/ml) which contained alpha-cyano-4-hydroxycinnamic acid (CHCA) 
diluted in acetonitrile/TFA/water (70/0.02/30, v/v) was also loaded and spotted onto 
the same spots and left to dry. The plate was loaded into the mass spectrometer. The 
results were recorded as a mass/charge ratio (m/z) against abundance and the masses 
observed were compared with the theoretical mass values that had been calculated 
earlier. 
 
2.4 Antimicrobial assays 
Three types of model microorganisms were used in these assays including the 
Gram-positive bacterium Staphylococcus aureus (S. aureus, NCTC 10788), the 
Gram-negative bacterium Escherichia coli (E.coli, NCTC 10418) and the pathogenic 
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yeast Candida albicans (C. albicans, NCPF 1467) to assess the peptide antimicrobial 
activity. 
2.4.1 Microorganism inoculation 
A bead each of S.aureus, E.coli and C.albicans was transferred from frozen stock to 
flasks with 100ml MHB (Muellar Hinton Broth). The flasks were incubated overnight 
(16-20h) in a vibrating incubator (Stuart, UK) at a speed of 150 rpm at 37 °C. For 
each organism, at least two McCartney bottles of 20ml MHB were placed in the 37°C 
incubator to warm up overnight.  
2.4.2 Peptide preparation 
Lyophilised peptide was weighed and dissolved in dimethyl sulphoxide (DMSO) to 
make the stock solution at a concentration of 512×10
2
 µM. Then the stock solution 
was double-diluted with DMSO to achieve a series of gradient stock concentrations: 
512, 256, 128, 64, 32, 16, 8, 4, 2, 1×10
2
 µM.  
2.4.3 Subculture 
To subculture, 500 µl of bacteria suspension from each flask, which had been 
incubated overnight, were transferred to McCartney bottles of pre-warm MHB and 
replaced in the vibrating incubator, to continue growth until the log phase. The optical 
density (OD) value of the subcultured bacteria was measured at 550 nm wavelength 
by a UV spectrophotometer. In table 2.11, the appropriate OD values of the three 
kinds of microorganism cultures and their corresponding concentrations are given.  
Table 2.11 The appropriate OD values for the three microorganisms used. 




S. aureus 1.5 h 0.23 1×108 
E. coli 1.0 h 0.41 1×108 
C. albicans 0.5 h 0.15 5×10
6
 
2.4.4 Minimum inhibitory concentration (MIC) measurements  
The MIC measurements were performed by using a 96-well plate. The cultures of 
S.aureus, E.coli and C.albicans were diluted to final concentrations of 5×105 cfu/ml 
when they had grown to the log phase and and dispersed completely in the Petri dish. 
One μl of peptide solution at each concentration and 99 μl diluted bacterial suspension 
were added to the wells in 5 replicates of the plate to form a series of final 
concentration of peptide at 512, 256, 128, 64, 32, 16, 8, 4, 2, 1 µM. The positive 
control was set with 100 μl of diluted bacterial suspension which indicated the growth 
of the organisms. And 100 μl of MHB medium were added as negative controls 
(blank control). In addition, 1 μl DMSO and 99 μl diluted bacterial suspensions in 5 
replicates were set as vehicle controls to observe the impact of 1% DMSO on the 
growth of bacteria. The 96-well plates were placed in a vibrating incubator to make 
the mixture well-distributed at 37 °C for 5 min and then were transferred to an 
incubator at 37 °C overnight. After overnight incubation, the growth of samples and 
controls were determined by using a Synergy HT plate reader (BioTek, USA) to 
detect the absorbance of each well at 550nm. MICs were defined as the lowest 
concentration at which no growth was detected.  
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2.4.5 Minimum bactericidal concentration (MBC) measurements 
The clear solution in each well from the MIC value to largest concentration was 
chosen for the assessment of minimum bactericidal concentration (MBC). 20 μl clear 
solution in 5 replicates were spotted onto a new MHA plate and then incubated at 
37°C overnight (16-20 h). Finally, the MBC value was obtained as that in which no 
colonies grew at the lower concentration.  
The antimicrobial assays should be repeated at least three times and the standard error 
of the mean (SEM) of three experiments was calculated to show the variability and 
repeatability. 
 
2.5 Haemolysis assay 
2.5.1 Peptide and control preparation 
The lpeptide was weighed and dissolved in PBS to prepare a stock solution with the 
concentration of 1024 µM. Then, the stock solution was 2-fold diluted in the ratio of 
1:1 in the PBS solution to achieve a series of gradient concentrations including 1024, 
512, 256, 128, 64, 32, 16, 8, 4, 2 µM. A positive control was prepared with Triton 
X-100 (Sigma Aldrich, St. Louis, MO, USA) diluted in PBS solution in which 1% 
(v/v) non-ionic detergent Triton X-100 (Sigma-Aldrich) can produce a 70% 
haemolytic effect. Meanwhile, PBS solution was regarded as a negative control (blank 
control) for the comparison of non-haemolytic effects.  
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2.5.2 Horse blood preparation 
The fresh horse blood (TCS Biosciences Ltd, Buckingham, UK) was gently mixed by 
shaking. Two ml of horse blood were transferred into a 50 ml universal tube. After 
that 30 ml of PBS solution were added into the universal tube to mix with the horse 
blood. The PBS and blood were mixed by a rotating mixer. Then the tube was 
centrifuged at 500 × g for 5 min. The supernatant was aspirated carefully and 
discarded. Then 30 ml of PBS solution were added into the universal tube again to 
wash the horse blood. This step was repeated until the supernatant was clear. When 
the supernatant was clear and discarded, 50 ml of PBS solution were added into the 
tube to disperse the red blood cells. The concentration of blood cells in the suspension 
was 4% (v/v).  
2.5.3 Haemolysis assay 
1.5 ml tubes were prepared and filled with 200µl prepared peptide solutions, positive 
control, negative control and vehicle control with five replicates of each. Then, 200µl 
of erythrocyte suspension was added slowly into each 1.5 ml tube. Therefore, the final 
concentration of peptide in each tube was same as concentrations in the MIC assay. 
All the samples and controls were incubated in the incubator (Genlab Limited, UK) at 
37°C for 2 h. Afterwards, all the 1.5 ml tubes were centrifuged at the speed of 500 × g 
for 5 min. 100 μl of supernatants from each tube were transferred into the wells of a 
96-well plate. The optical density (OD) values were measured at 550nm by using a 
Synergy HT plate reader (BioTek, USA). The percentage of haemolysis was 
calculated using the following formula and a graph was drawn.  
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Haemolysis% = (A-AO) / (AX-AO) × 100% 
Where A represents the OD (λ550) of peptide/ erythrocyte mixture, AX the OD (λ550) 
of the positive control and AO the OD (λ550) of the negative control.  
 
2.6 MTT cell viability assay 
This process was performed in a microbiological safety cabinet at an appropriate 
containment level (Class 2). 
The cells used in this study were PC-3 (Human Prostate Carcinoma (GIV) cell line), 
NCI-H157 (non-small cell lung cancer), MCF-7 (breast cancer non-tumourigenic 
mammary gland) and U251MG (Human Neuronal Gliblastoma(Astrocytoma)). The 
PC3 and the NCI-H157 were cultured in RPMI-1640 medium (Invitrogen, Paisley, 
UK), whereas the U251MG and MCF-7 were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with high glucose (25 mM) (Sigma, St. Louis, MO, USA) 
in a humidified environment containing 5% CO2 at 37°C. Importantly, both the 10% 
foetal bovine serum (FBS) (Sigma, UK) which provided nutrition for cells growing 
and 1% penicillin streptomycin solution (Sigma, UK) which inhibited the growth of 
bacteria were also added into the medium.  
2.6.1 Resuscitation of frozen cell lines 
The tubes containing the frozen cells were transferred from the -80ºC freezer storage 
to a water bath which was set at 37°C. The tubes were gently flicked to increase the 
thawing of the cells. Then, all the cells were transferred into an 75 cm
2
 culture flask 
(Nunc, Denmark) with pre-warmed 15 ml medium drop by drop and swayed gently 
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and slowly to dilute the cryoprotectant DMSO. The culture flask was then incubated 
in a CO2 incubator (37°C, 5% CO2) overnight. The next day (after 24 h), when the 
cells had become adherent, the spent medium with DMSO was discarded and fresh 
medium was added to the culture flask. The medium with FBS (Foetal Bovine Serum) 
and PS (Penicillin Streptomycin Solution) was used in this process. 
2.6.2 Cell subculture and passage 
In order to prevent the dying of cells, they should be sub-cultured regularly as soon as 
they reached confluence. The flask was placed vertically and the spent culture 
medium was removed with a transfer pipette carefully. Then 10 ml of PBS were 
added into the flask followed by gentle swaying to wash the cells. The PBS was 
removed by the same method with a transfer pipette and 1000 μl 1X Trypsin/EDTA 
(Invitrogen, UK) was added into the culture flask in order to strip the cells from the 
surface of the flask. Then the flask was incubated at 37°C for 2-5min until the cell 
suspension became turbid. A microscope was used to observe the state of the cells in 
the flask to ensure that all the cells were detached and floating. Subsequently, 10 ml 
pre-warmed medium was added into the culture flask to cease the digestion, followed 
by cell aspiration. The suspension in the flask was transferred into a 15ml universal 
tube and was centrifuged at 350 × g for 5 min. The supernatants were then discarded 
and 5 ml pre-warmed medium were added into the 15 ml universal tube. The cells in 
the tube were mixed thoroughly. Finally, the cell suspension was transferred into a 
new flask and diluted by medium to a volume of 10ml then incubated in a humidified 
atmosphere at 37°C under 5% CO2. The medium in the flask should be changed every 
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2 days or changed when the medium colour changed. The second generation of cells 
could be used for the MTT cell viability assay or continuing passage when they 
reached confluency.  
2.6.3 Cell counting 
Cell counting is important in this assay because of the need of comparison between 
parallel experiments and the repeatability of experiments. The cell counting was 
carried out using an AS1000 Improved Neubauer haemocytometer (Hawksley,UK). 
The haemocytometer slide and coverslip were washed by water and dried. The 
counting area on the haemocytometer slide was covered by the coverslip. The 
previous procedures including cell washing, digestion, transfer, centrifugation and 
discarding of media were used with all subsequent cell passages. Five ml of 
pre-warmed medium was added into a 15 ml universal tube with cells and then the 
tube contents were mixed evenly by vortexing. After that, 50 μl of cell suspension and 
an equivalent volume of 0.4% (w/v) trypan blue (Invitrogen, UK) were mixed 
together. The mixture was transferred to the haemocytometer slide on both counting 
area notches on the top and the bottom. A microscope was used to count the cells. The 
counting area of the haemocytometer slide was divided into nine areas. The dead cells 
could be dyed by Trypan Blue while the live cells remained transparent. Three 
random areas were chosen and the numbers of live cells were counted. The cell 
concentration was determined by use of the following formula: 




 × 2 
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2 represented the dilution factor. Finally, the volume of cells and medium were 
calculated to achieve the desired concentration of 5×10
4
 cells per ml. 
2.6.4 Cell seeding 
An appropriate volume of cell suspension and pre-warmed medium were mixed and 
diluted to the final concentration of 5000 cells/100μl in the tray. Then, 100 μl samples 
of cell suspension were seeded in each well of the 96-well plate for cell attachment. 
After that, the 96-well plate was incubated at 37°C under 5% CO2 in a humidified 
atmosphere for 24 h. 
2.6.5 Cell starvation 
All media from the wells was removed and discarded as cleanly as possible and 100 
μl of pre-warmed FBS-free medium was added into each well. Subsequently, the 
96-well plate was incubated at 37°C under 5% CO2 in humidified surroundings for 
6-12 h in order to starve the cells which can eliminate the impact of FBS in the 
parallel assay.  
2.6.6 Peptide preparation 
The lyophilised peptide was weighed and dissolved in DMSO to make a stock 
solution with a final concentration of 10
-2
 M. For preliminary screening of the 
anticancer functions, the peptide was diluted in FBS-free medium to make a 
concentration of 10
-4 
M. For gradient experiment, 70 μl of the stock solution was 















 M.  
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2.6.7 Peptide loading 
The 96-well plate was taken from the incubator and the FBS-free medium was 
discarded carefully by pipette. Then 100μl of each prepared peptide solution were 
transferred into the wells with 5 replicates. Fresh FBS-free medium was added as the 
control group and an equal volume of 1% DMSO solution was also added as a vehicle 
control which reflected the impact of 1%DMOS on the cell growth. Lastly, the 
96-well plate was incubated at 37°C in a humidified environment containing 5% CO2 
for 24 h. 
2.6.8 MTT assay 
After 24 h of incubation, the plate was removed and 10μl of 5mM yellow-coloured 
MTT solution (Sigma, UK) were added into each well in a dark environment. The 
plate was knocked on the table gently to make sure the MTT sank down upon the cells 
that were attached to the bottom of the plate. Then the plate was incubated for 4-6 h. 
After this, the supernatants were discarded completely by use of a syringe. Then 100 
μl of DMSO were added into each well quickly followed by gentle agitation in the 
orbital incubator (Stuart, UK) for 10 min in order to dissolve the insoluble purple 
formazan crystals. Then the plate was placed in a shaking incubator with a shaking 
rate of 250 rpm. Finally, Synergy HT plate reader (BioTek, Winooski, VT, USA) was 
used to measure the absorbance of the coloured solution at 570 nm. The statistical 





Chapter 3. Results 
 
3.1 Animals and skin secretion harvesting 
The skin secretion of Pelophylax esculentus was successfully extracted and 
lyophilised to store. 
 
3.2 Molecular cloning 
A cDNA encoding the precursor of a novel peptide was successfully cloned from the 
library during RACE-PCR. The nucleotide and translated open-reading frame amino 
acid sequence of the cDNA is shown in Figure 3.1. The predicted novel peptide is 
comprised of 13 amino acid residues and was named QUB-1342.  
 
Figure 3.1: Nucleotide and translated open-reading frame amino acid sequence of 
cDNA encoding prepro-QUB-1342 cloned from Pelophylax esculentus skin 
secretion-derived library. The putative signal peptide and the mature peptide 
sequences are both single-underlined and the stop codon is indicated by an asterisk. 
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3.3 Structural characterisation of peptide QUB-1342 
3.3.1 RP-HPLC chromatography of synthetic peptide QUB-1342 
After solid-phase peptide synthesis, the crude product QUB-1342 was analysed by 
RP-HPLC and the result is shown in Figure 3.2. The major peaks 1, 2, 3 and 4 were 
further subjected to MALDI-TOF MS analysis. Among these, peaks 3 and 4 were 
proven to be representative of the expected product.  
Figure 3.2 RP-HPLC chromatogram of synthetic QUB-1342. 
 
3.3.2 MALDI-TOF MS of QUB-1342 
The crude solid-phase synthesis product of QUB-1342was analysed by MALDI-TOF 
MS, and the spectrum obtained is shown in Figure 3.3. Its theoretical molecular mass 
is 1341.68 Da. The observed mass is 1342.03 Da, with a peak bound with a sodium 
ion as 1364.03 Da and a potassium ion as 1381.00 Da.  



























Figure 3.3 MALDI-TOF mass spectrum of synthetic peptide QUB-1342 
 
3.4 MIC assay and MBC assay 
The MIC assay of QUB-1342 was performed on S. aureus, E.coli, and C.albicans. 
The results are shown in Figure 3.4. In S.aureus, QUB-1342 started to inhibit the 
bacteria growth at 64μM. The rise of the curve when the concentration approaches 
512μM was considered to be caused by precipitation of the peptide. However, this did 
not produce any effect on E.coli or C.albicans in the concentration range employed 
that is standard for all AMPs tested in the lab. The experiment was repeated three 
times.  
The MBC assays showed that S.aureus was able to grow at the all the tested 
concentration of QUB-1342, indicating that it did not possess bactericidal activity at 
the concentration up to 512 μM.  
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Figure 3.4 MIC of QUB-1342 against S.aureus. E.coli and C.albicans. Each 
experiment was performed as 15 replicates. 
 
3.5 Haemolysis assay 
The results of the haemolysis assay are shown in Figure 3.5. The peptide did not 
produce a haemolytic effect at concentrations between 1 and 256μM. The average 
haemolytic ratio when the concentration reached 512μM was 6.47%. The peptide is 
thought to produce little haemolytic effect. 
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Figure 3.5 The haemolytic effect of QUB-1342. In total 5 replicates were subjected to 
the assay.  
 
3.6 MTT assay 
The QUB-1342 was prepared at concentration of 10
-4
 M for preliminary screening and 
the results were shown in Table 3.1. For all of the viability was above 50%, indicating 
that QUB-1342 did not show obvious growth inhibition on the cancer cell lines tested 







Table 3.1 The cell viability of cancer cell lines U251-MG, H157, PC3, and MCF-7 at 
peptide concentration of 10
-4
 M. 
 Cancer cell lines 
U251-MG H157 PC-3 MCF-7 





Chapter 4. Discussion 
 
Amphibians are widely distributed on the Earth. In order to avoid external pathogen 
invasion and adapt to the needs of diverse environments, they rely on secretions from 
skin glands, which contain a wide variety of complex functional peptides. These 
peptides have an amazing advantage in species and quantity compared with those in 
mammals. Ranidae, the third family of Anura, with 50 genera and 650 species, is the 
most widely distributed in almost every continent. Most of the frogs can synthesise 
and secrete a variety of active components. For their molecular diversity, unique 
mechanism of action on bacteria and mild side effects, the AMPs from Ranidae are 
worth of study and expected to be novel clinical drugs as antibiotics, antivirals and 
antineoplastics. 
 
Activities of AMPs are closely related to amino acid form and structure, including 
length, charge, hydrophobicity, hydrophobic moment, helicity, and so on (Dathe and 
Wieprecht, 1999). The peptide-membrane interaction is supported by a sensitive 
balance determined by those factors. Helicity is more related to the interaction to 
membranes with neutral charge than to negatively charged bilayers, therefore is one of 
the influencing factors of haemolysis. On the contrary, the modification of introducing 
positive charge is more conducive to targeting the Gram-positive and Gram-negative 




In these experiments, the peptide originated from the skin secretion of Pelophylax 
esculentus and was defined as a typical peptide of the temporin family through 
analysis of net charge, length and consensus sequence (FLPLIASLLSKLL-NH2) 
derived by Wade (2000). Temporins are a vast group of peptides containing 10-14 
amino acid residues with C-terminal amidation, containing net charges from 0 to +3. 
In most cases, naturally produced temporins contain a single basic amino acid, which 
mediates their effect against Gram positive bacteria, such as clinically isolated 
methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus 
faecium and Enterococcus faecalis. In temporins, the length and net charge are two 
significant factors that are correlated to the pharmacological effects. For example, 
peptides with zero basic amino acids that contain net charges of 0 to +1, only possess 
weak or absent antimicrobial effects, such as temporin-1Ja, C, D, or E (Simmaco, et.al, 
1996). One of the most active peptides, temporin-L, with a net charge +3, not only 
exhibits a strong effect against Gram positive, Gram negative bacteria and fungi, but 
is also active against parasites, cancer cells, and mammalian cells (Rinaldi, et al., 
2002). There is an exception to this rule, in that temporin-1Od does not contain 
positive amino acids, but still has a strong antibacterial activity, with an MIC against 
S. aureus of 13μM (Kim, Iwamuro, Knoop and Conlon, 2001). Furthermore, when the 
number of residues reduces to 10, the activities will also vanish, such as in temporin H 
and K (Mangoni, 2006). However, exceptions exist again in temporin-SHf, a peptide 
with an ultrashort length of 8 amino acid residues, which is active against Gram 
positive, Gram negative bacteria and fungi (Abbassi, et al, 2010). 
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QUB-1342 shows a weak bacteriostatic effect against the Gram positive bacterium 
S.aureus, with an MIC=64μM. Only a small amount of haemolysis occurs compared 
to the positive control Triton X-100 at high concentrations. The peptide scarcely 
exhibited any haemolysis towards horse RBC. Although it is highly hydrophobic 
according to the retention time in RP-HPLC (Figure 3.2), its disruption of 
phospholipids in the membranes of RBCs is very weak. In addition, the MIC value is 
not in the range of the haemolytic concentration. 
 
To better understand its structure-function relationships, QUB-1342 was analysed by 
the Peptide Property Calculator (www.pepcalc.com). The hydrophobic amino acid 
residues occupy most sites, including one aromatic, seven aliphatic amino acid 
residues, one proline and two glycines. QUB-1342 has no basic amino acid residue, 
and only possesses one net charge at pH 7. According to the characteristics of 
temporins, the lack of positive charge is the main cause of the weak antimicrobial 
activity.  
 
By comparison through NCBI-BLAST and the Antimicrobial peptide database, 
QUB-1342 was found to be 92.3% identical to two AMPs, temporin-SHb and 
temporin-1CSc. 
 
Table 4.1 Comparison of amino acid sequence, net charge and antimicrobial activity 
of QUB-1342, temporin-SHb (Abbassi, et al, 2008), temporin-1CSc (Conlon, et al., 
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2007), temporin-1P (temporin-1CSa) (Conlon, et al, 2007), temporin-LF1 (Guo and 
Hu, 2014), and temporin-CSb (Conlon, et al., 2007) 








FLPIVTGLLSGLL-NH2 +1 S. aureus 64 
E. coli ND 
C. albicans ND 
temporin-SHb Pelophyla
x saharica 
FLPIVTNLLSGLL-NH2 +1 S. aureus 58 
E. coli >116 











FLPIVGKLLSGLL-NH2 +2 S. aureus 8 




FLPFVGKLLSGLL-NH2 +2 S. aureus 12.5 
temporin-CSb Rana 
cascadae 
FLPIIGKLLSGLL-NH2 +2 S. aureus 8 
E. coli 128 
ND: no detected activity 
The basic amino acid residue is marked in red. 
*Temporin-1P was reported against S.aureus (MIC=110 μM) (Goraya, Wang and Li, 
2000). The same sequence named temporin-1CSa was reported by Conlon (2007) 
with MIC=8μM against S.aureus. 
 
From Table 3.1, the three homologues, QUB-1342, temporin-SHb, and 
temporin-1CSc, with one amino acid difference, respectively, share similar properties. 
All of the three peptides have no basic amino acid residues, and produce weak 
bacteriostatic effects on Gram positive bacteria only. The distinctions in leucine and 
isoluecine at position 4, and asparagine and glycine at position 7 do not cause much 
change in activities. Investigation on the structure-activity relationship of temporin A 
and its synthetic homologues illustrate several vital positions that influence the 
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antimicrobial effect (Wade, et al, 2000): the N-terminal hydrophobic group, basic 
amino residue at position 7, large side chain of hydrophobic residues of position 5 and 
12. In addition, the replacement of leucine from isoleucine at amino acid position 5 or 
12 will enhance its antibacterial ability. In comparison, the 4th-position distinction 
between Temporin-1Ef and Temporin-CSc seems to not work, suggesting that it is not 
a crucial site.   
 
However, the activity changed dramatically in temporin-1P (temporin-1CSa), with 









. Obviously, the key role is the substitution 
of the basic amino acid at 7
th
 position as mentioned in temporin A study. The higher 
the net charge, the stronger antibacterial ability is promoted. It is also proven in 
temporin-LF1 and temporin-CSb. As for QUB-1342 and the two homologues, other 
requirements of hydrophobic residues are matched except a basic amino acid, but the 
activity is weak. Therefore, it is assumed that the 7
th
 basic amino acid residue is a 
more crucial factor in temporin properties than others.  
 
Temporins are peptides with low haemolytic side effects and so does QUB-1342. 
Studies on the helix structure of temporin L and its synthetic homologues, indicated 
that the Pro
3
 residue helps decrease haemolytic activity (Saviello , et al, 2010). Since 
the high haemolytic effect is induced by the high and complete helicity, the 
introduction of Pro
3
 is good for forming a turning structure at the N-terminus, 
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therefore cutting down on the unexpected effects. In addition, the replacement of 
native Pro
3
 in temporin A increased the helical region at the N-terminus, but had little 
antimicrobial activity promotion effects, confirming that the helix is more involved in 
haemolysis than in antimicrobial activity.  
 
Leucine and phenylalanine are known to help in membrane-anchoring interactions 
(Meijer, Spruijt, Wolfs, and Hemminga, 2001). Temporin-1Od, though without any 
basic amino acid residues, is relatively potent towards S.aureus with an MIC=13μM. 
It may attribute to the special structure or function leucine and phenylalanine 
displayed, suggesting that these two amino acids help to enhance the potency of 
AMPs.  
 
However, most mechanism of temporins still remains unclear. Due to the small charge 
and the short length, every residue change can produce great functional changes. 
Through the existing literature on the speculation of functions of residues and 
structures, several hypotheses to improving the antimicrobial effects of temporins 
have been made: 
1. Substitute with basic amino acid residues. As the natural peptide contains Lys
7
, it is 
assumed that replacement of arginine and histidine will provide similar properties. 
From the consensus sequence, we can know that the 11
th
 residue is also a typical site 
for a basic amino acid, which could be tested. 
2. Substitute with leucine. This may be restricted by position differences in the chain.  
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3. Maintain or introduce proline at position 3 to promote lower haemolysis. As for the 
already discovered temporins with broad spectra of action and high potency but high 
haemolytic activity, it may be of great benefit to lower the side effects and accelerate 
the development of clinical use.  
 
In summary, the study of QUB-1342 has implications for detecting pharmacological 
functions, and speculating on the structure-activity relationships of the temporin 
family. The temporins and their homologues are expected to be novel candidate drugs 
for the clinic, for small design alternations in amino acid sequence can result in 
dramatic improvements in antimicrobial activity but maintain a weak haemolytic 
activity. These factors are significant for solving obstacles provided through antibiotic 
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